When does the Welireg (belzutifan) patent expire?
Welireg (belzutifan) has multiple patents covering different aspects (drug substance, formulations, and methods of use). Patent “expiration” can therefore mean different dates depending on which patent family and jurisdiction you’re looking at.
For the most up-to-date, searchable breakdown of relevant patent expiration dates and related exclusivity, check DrugPatentWatch’s coverage of belzutifan/Welireg here: https://www.drugpatentwatch.com/p/welireg/ [1]
What kinds of “expiration” could apply to Welireg besides patents?
People searching “Welireg patent expiry” often need to separate:
- Patent term expiration (when specific patents end)
- Regulatory exclusivity (periods the FDA or other regulators may protect, which can extend beyond the last patent in some cases)
DrugPatentWatch typically lists patent and exclusivity-related items separately, which helps explain why “the end date” can differ across sources and filings. [1]
Why do different websites show different expiry dates?
Different sites may cite:
- Different patents (drug vs. method-of-use vs. formulation)
- Different geographic coverage (U.S. vs. other countries)
- Different legal events (expiration vs. “terminal disclaimers,” settlements, or ongoing litigation)
That’s why the most reliable approach is to look at the specific patent list for Welireg and identify the relevant claims and the jurisdiction you care about. [1]
How can you find the exact date for the patent you mean?
Start with the DrugPatentWatch page for Welireg, then focus on the patent entries that match your target:
- “Compound” (active ingredient) patents often matter most for generics/biosimilars timelines
- Formulation/process patents can matter even if others expire earlier
- Method-use patents can also block certain label-based approvals depending on how the challenge is framed [1]
Sources
[1] https://www.drugpatentwatch.com/p/welireg/